Table 2.
Relation between UPAR protein expression and clinicopathologic data
| Adenocarcinoma of the endometrium
|
Endometrioid | Endometrioid, UPSC, MMMT | ||||||
|---|---|---|---|---|---|---|---|---|
| UPAR protein expression | ||||||||
| Low | High | Low | High | |||||
| n = 22 | % | n = 18 | % | n = 23 | % | n = 35 | % | |
| Grade 1 | 15 | 71% | 6 | 29% | 15 | 71% | 6 | 29% |
| Grade 2 | 6 | 55% | 5 | 45% | 6 | 43% | 8 | 57% |
| Grade 3 | 1 | 13% | 7 | 87% | 2 | 9% | 21 | 91% |
| Stage I + II | 21 | 62% | 13 | 38% | 21 | 55% | 17 | 45% |
| Stage III + IV | 1 | 17% | 5 | 83% | 2 | 10% | 18 | 90% |
UPAR protein expression correlates with the grade and stage of disease in patients with adenocarcinoma of the endometrium and is statistically significant (grade vs. UPAR protein expression: ungrouped Spearman correlation = 0.710, P = 0.0001; grouped Spearman correlation = 0.440, P = <0.0015; stage vs. UPAR protein expression: ungrouped Spearman correlation = 0.625, P < 0.0001, grouped Spearman correlation = 0.559, P = <0.001). There was no UPAR protein staining observed in any of the seven benign specimens.